Updated IV and SC Results from a Phase I Dose Escalation Study of Forimtamig with RRMM Patients скачать в хорошем качестве

Updated IV and SC Results from a Phase I Dose Escalation Study of Forimtamig with RRMM Patients

Dr. Carmelo Carlo-Stella presents the updated intravenous and subcutaneous results from a Phase I dose escalation study of Forimtamig a GPRC5DxCD3 T-Cell engaging bispecific antibody with relapsed/refractory multiple myeloma patients. Background: Despite advances in treatment, almost all pts with newly diagnosed multiple myeloma (MM) eventually relapse and progression-free survival decreases with each subsequent line of therapy. New treatments that target novel antigens and/or have novel mechanisms of action (MOAs) are needed. GPRC5D is a G-protein coupled receptor that is overexpressed on malignant plasma cells. Expression on normal tissue is limited to skin (hair follicles and eccrine glands) and testis (seminiferous tubules). In a Phase I study (NCT04557150), RG6234, a GPRC5DxCD3 T-cell engaging bispecific antibody with a novel 2:1 configuration, was highly active in pts with RRMM and had a safety profile consistent with its MOA and target distribution when given IV (Hasselbalch Riley et al. EHA 2022). We report updated IV and first SC results. Conclusions: RG6234 is highly active in pts with heavily pretreated RRMM when administered IV or SC. AEs are consistent with its MOA and target distribution. Evaluation and optimization of IV and SC dosing is ongoing. Authors: Carmelo Carlo-Stella, MD, PhD, Rita Mazza, MD, Salomon Manier, MD, PhD, Thierry Facon, Sung-Soo Yoon, MD, PhD, Youngil Koh, MD, PhD, Simon J Harrison, MD, Jeremy Er, MD, Antonio Pinto, MD, Francesco Volzone, MD, Giulia Perrone, MD, Paolo Corradini, MD, Titouan Cazaubiel, MD, Cyrille Hulin, Cyrille Touzeau, Philippe Moreau, MD, Enrique M. Ocio, Carmen Maria Montes Gaisan, MD, Rakesh Popat, MD, PhD, Sarah Leong, MD, Fritz Offner, MD, PhD, Paula Rodriguez Otero, Ana Alfonso-Pierola, MD, PhD, Ann-Marie E Bröske, Iryna Dekhtiarenko, PhD, Hans-Joachim Helms, PhD, Sara Belli, PhD, Eva Rossmann, MD, PhD, Tanja Fauti, PhD, Jan Eckmann, Tom Moore, MD, Meike Schneider, MD, Wolfgang Jacob, PhD, Martin Weisser, MD, PhD, Martin Hutchings, MD, PhD and Caroline Hasselbalch Riley, MD, PhD ASH Abstract #161: https://ash.confex.com/ash/2022/webpr... _______________ Improving Lives | Finding the Cure Founded in 1990, the International Myeloma Foundation (IMF) is the first and largest organization focusing specifically on multiple myeloma. The IMF’s reach extends to more than 525,000 members in 140 countries worldwide. The IMF is dedicated to improving the quality of lives of myeloma patients while working toward prevention and a cure through our four founding principles: Research, Education, Support, and Advocacy. Subscribe to our channel:    / imfmyeloma   Visit our website at: https://www.myeloma.org Find us online: Facebook: @myeloma |   / myeloma   Twitter: @IMFMyeloma |   / imfmyeloma   Instagram: @imfmyeloma |   / imfmyeloma   LinkedIn:   / international-myeloma-foundation   Support the IMF | Donate Now! https://secure.myeloma.org/page/40697... Category Nonprofits & Activism License Standard YouTube License In most cases, captions are autogenerated by YouTube.